Related references
Note: Only part of the references are listed.Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
Chinami Masuda et al.
CLINICAL & EXPERIMENTAL METASTASIS (2020)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
Antonio Passaro et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma
Po-Hao Feng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer
Yasuhiro Chikaishi et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Ayseguel Ilhan-Mutlu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Benjamin Besse et al.
CLINICAL CANCER RESEARCH (2015)
Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features
Akimasa Sekine et al.
LUNG CANCER (2012)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases
Michael L. DiLuna et al.
CANCER (2007)
Share Paper
